International Journal of Innovative Technologies in Social Science

e-ISSN: 2544-9435

Operating Publisher
SciFormat Publishing Inc.
ISNI: 0000 0005 1449 8214

2734 17 Avenue SW,
Calgary, Alberta, T3E0A7,
Canada
+15878858911
editorial-office@sciformat.ca

ARTICLE TITLE	LEPTIN RESISTANCE AND ITS ROLE IN THE PATHOPHYSIOLOGY OF OBESITY AND METABOLIC DISORDERS: A LITERATURE REVIEW
DOI	https://doi.org/10.31435/ijitss.2(50).2026.5113
RECEIVED	02 March 2026
ACCEPTED	17 June 2026
PUBLISHED	25 June 2026
LICENSE	The article is licensed under a **Creative Commons Attribution 4.0 International License.**

LEPTIN RESISTANCE AND ITS ROLE IN THE PATHOPHYSIOLOGY OF OBESITY AND METABOLIC DISORDERS: A LITERATURE REVIEW

Karol Dąbek *(Corresponding Author, Email: karoldabek2000@interia.pl)*
John Paul II Municipal Hospital in Rzeszów, 4 Rycerska St., 35-241 Rzeszów, Poland
ORCID ID: 0009-0005-6152-3870

Kamila Czyżak
John Paul II Municipal Hospital in Rzeszów, 4 Rycerska St., 35-241 Rzeszów, Poland
ORCID ID: 0000-0002-8866-5810

Urszula Marzec
Stefan Cardinal Wyszyński Provincial Specialist Hospital SPZOZ in Lublin, Aleja Kraśnicka 100, 20-718 Lublin, Poland
ORCID ID: 0009-0000-6348-184X

Aleksandra Cyrkler
Stefan Cardinal Wyszyński Provincial Specialist Hospital SPZOZ in Lublin, Aleja Kraśnicka 100, 20-718 Lublin, Poland
ORCID ID: 0009-0001-6865-7450

Natalia Cieślak
Medical University of Lublin, Lublin, Poland
ORCID ID: 0009-0004-6355-8164

Agata Chodkowska
Medical University of Lublin, Lublin, Poland
ORCID ID: 0009-0000-5006-3040

Eliza Rajca
Wojewódzki Szpital Zespolony, Kielce, Świętokrzyskie, Poland
ORCID ID: 0009-0005-6024-4298

Agnieszka Giza
Independent Public Hospital No. 4 in Lublin, ul. Dra K. Jaczewskiego 8, 20-090 Lublin, Poland
ORCID ID: 0009-0002-5741-3482

Paulina Giza
Medical University of Warsaw, Warsaw, Poland
ORCID ID: 0009-0004-7637-5906

Karolina Wymoczył
Stefan Cardinal Wyszyński Provincial Specialist Hospital SPZOZ in Lublin, Aleja Kraśnicka 100, 20-718 Lublin, Poland
ORCID ID: 0009-0004-7326-8013

ABSTRACT

Introduction: Obesity is a global health crisis linked to severe metabolic comorbidities. Leptin, a key hormone regulating energy homeostasis, fails to suppress appetite in obese individuals despite hyperleptinemia—a state known as leptin resistance.
Methods: This study presents current knowledge on leptin resistance and its role in obesity and metabolic disorders. A narrative literature review was conducted using PubMed, Scopus, and Web of Science, focusing on recent molecular studies, neuroendocrine mechanisms, and cardiometabolic consequences.
Key findings Leptin resistance involves a multi-level failure of the signaling axis, including impaired blood-brain barrier transport, LepRb receptor downregulation, and JAK2-STAT3 cascade disruption. Key molecular drivers include intracellular inhibitors (SOCS3, PTP1B), endoplasmic reticulum (ER) stress, and diet-induced hypothalamic neuroinflammation. This state leads to severe consequences, such as ectopic lipid accumulation, lipotoxicity, and peripheral insulin resistance.
Conclusion: Leptin resistance is a central pathogenic mechanism in obesity and metabolic syndrome. Targeting specific molecular blockades through novel leptin sensitizers and incretin-based polypharmacology represents a highly promising frontier for future anti-obesity therapies.

KEYWORDS

Leptin Resistance; Obesity; Hypothalamus; Neuroinflammation; Endoplasmic Reticulum Stress

CITATION

Karol Dąbek, Kamila Czyżak, Urszula Marzec, Aleksandra Cyrkler, Natalia Cieślak, Agata Chodkowska, Eliza Rajca, Agnieszka Giza, Paulina Giza, Karolina Wymoczył. (2026) Leptin Resistance and Its Role in the Pathophysiology of Obesity and Metabolic Disorders: a Literature Review. *International Journal of Innovative Technologies in Social Science*. 2(50). doi: 10.31435/ijitss.2(50).2026.5113

Introduction

Obesity is a global pandemic (BMI ≥ 30 kg/m²) characterized by severe metabolic comorbidities, including type 2 diabetes, non-alcoholic fatty liver disease (NAFLD), and cardiovascular disease. Modern endocrinology recognizes it as a complex neuroendocrine disorder driven by a mismatch between evolutionary energy-conserving traits and the modern obesogenic environment (World Health Organization, 2021). Historically, the conceptual framework of body weight regulation evolved from early parabiosis experiments and the "lipostatic hypothesis," culminating in the landmark 1994 discovery of leptin. This adipocyte-derived hormone serves as a critical metabolic signal, crossing the blood-brain barrier to powerfully suppress appetite and increase energy expenditure (Neel, 1962; Farooqi et al., 1999). While rare congenital leptin deficiency results in severe obesity that is highly responsive to exogenous leptin therapy, the vast majority of obese individuals exhibit profound hyperleptinemia. The failure of this abundant circulating hormone to induce expected weight loss is clinically defined as leptin resistance. Once established, this maladaptive state aggressively defends elevated body weight and directly exacerbates systemic metabolic dysregulation (Gruzdeva et al., 2019; Myers et al., 2010). This review systematically examines the precise molecular mechanisms underlying central leptin resistance. We will specifically explore defective blood-brain barrier transport, intracellular blockades via SOCS3 and PTP1B, endoplasmic reticulum (ER) stress, and diet-induced hypothalamic neuroinflammation (Cui et al., 2017; de Git & Adan, 2015). Furthermore, we will elucidate the crosstalk between leptin and insulin resistance, highlighting emerging pharmacological strategies to restore metabolic homeostasis.

Methodology

A literature search was conducted in PubMed, ScienceDirect, and Google Scholar, focusing on the most recent studies on the molecular mechanisms of leptin resistance in obesity. Keywords included “leptin resistance”, “obesity”, “hypothalamus”, and “neuroinflammation”, with emphasis on intracellular signaling pathways and cardiometabolic risk factors.

Results

Physiology of Leptin and Energy Homeostasis

Leptin is a highly conserved, 16-kDa, 146-amino-acid polypeptide hormone. In humans, it is encoded by the *LEP* gene located on chromosome 7q32.1 (Farooqi et al., 1999). It is synthesized and secreted predominantly by mature white adipocytes in direct proportion to the volume of intracellular lipid droplets. While minor quantities of leptin are produced in the gastric mucosa (regulating short-term satiety), skeletal muscle, placenta, and mammary glands, the adipocyte-derived fraction is the exclusive driver of systemic energy homeostasis (Wang et al., 2026). To exert its profound biological actions, circulating leptin must bind to the leptin receptor (LepR or OB-R), which is encoded by the *LEPR* gene located on chromosome 1p31.3. LepR is a single-transmembrane-domain receptor belonging to the class I cytokine receptor superfamily, sharing significant structural homology with the gp130 subunit of the IL-6 receptor (Cani et al., 2007). Through extensive alternative mRNA splicing, several distinct isoforms of the receptor are generated (LepRa through LepRf). All isoforms share an identical extracellular domain—comprising two cytokine receptor homology (CRH) domains separated by an immunoglobulin-like (Ig-like) domain, and two membrane-proximal fibronectin type III (FnIII) domains, which are absolutely essential for leptin binding and subsequent receptor activation (Gautron & Elmquist, 2011). Crucially, the isoforms differ drastically in their intracellular signaling capabilities. Only the long isoform, LepRb, contains a full-length intracellular signaling tail of approximately 300 amino acids. This intracellular domain is defined by the presence of specific structural motifs, notably the proline-rich Box 1 and Box 2 motifs, which are required for the constitutive, non-covalent association of the non-receptor tyrosine kinase, Janus kinase 2 (JAK2). Furthermore, the LepRb intracellular tail contains three critical, highly conserved tyrosine residues (Tyr985, Tyr1077, and Tyr1138) that serve as indispensable phosphorylation docking sites for downstream signal transducers (Gautron & Elmquist, 2011; Cani et al., 2007).

Blood-Brain Barrier (BBB) Transport Dynamics

Because LepRb is predominantly expressed within the central nervous system, peripherally secreted leptin must cross the highly restrictive blood-brain barrier (BBB). This is not a passive diffusion process; rather, it is mediated by a highly specific, saturable, active transcytosis mechanism. This transport is primarily facilitated by the short receptor isoform, LepRa, which is abundantly expressed on the luminal surface of brain capillary endothelial cells and the choroid plexus. Recent neuroanatomical studies have also highlighted the critical role of tanycytes—specialized ependymo-glial cells lining the floor of the third ventricle. Tanycytes capture circulating leptin from the fenestrated capillaries of the median eminence (a circumventricular organ lacking a typical BBB) and actively transport it directly into the cerebrospinal fluid (CSF) and the parenchyma of the arcuate nucleus, ensuring rapid delivery to the primary metabolic integration centers (Wang et al., 2026).

Neuroanatomical Targets and Hypothalamic Circuitry

Once within the CNS, leptin acts on a vast neuroanatomical network, but its primary target is the hypothalamus. LepRb is densely expressed in the arcuate nucleus (ARC), ventromedial hypothalamus (VMH), dorsomedial hypothalamus (DMH), and paraventricular nucleus (PVN) (Clegg et al., 2006). The ARC represents the "first-order" sensory center for leptin, containing two functionally opposing, yet highly interconnected, neuronal populations. POMC/CART neurons co-express proopiomelanocortin (POMC) and cocaine- and amphetamine-regulated transcript (CART). Leptin directly depolarizes and activates these neurons. POMC is enzymatically cleaved by prohormone convertases into alpha-melanocyte-stimulating hormone (α-MSH). α-MSH is released from axonal terminals to act as a potent agonist on melanocortin-4 receptors (MC4R) located on "second-order" neurons in the PVN and lateral hypothalamus (LH). This MC4R activation leads to profound appetite suppression (anorexia), increased thermogenesis via brown adipose tissue (BAT) activation, and the upregulation of Brain-Derived Neurotrophic Factor (BDNF).AgRP/NPY neurons: These neurons co-express agouti-related peptide (AgRP) and neuropeptide Y (NPY), which are the most potent orexigenic (hunger-inducing) neuropeptides in the mammalian brain. Leptin strongly hyperpolarizes and

directly inhibits these neurons. Crucially, AgRP acts as a competitive inverse agonist at the MC4R, effectively blocking the anorexigenic action of alfa-MSH. Furthermore, AgRP neurons release the inhibitory neurotransmitter GABA directly onto POMC neurons, suppressing their activity (Clegg et al., 2006). Thus, healthy leptin signaling executes a dual mandate: it simultaneously activates satiety circuits while actively silencing hunger and foraging circuits.

Intracellular Molecular Signaling Pathways: The Holy Trinity of Leptin Action

Because LepRb lacks intrinsic enzymatic kinase activity, the binding of leptin to the extracellular CRH domains induces a profound conformational change (receptor oligomerization) that approximates the intracellularly associated JAK2 molecules. This allows JAK2 to trans-phosphorylate and fully activate itself. The active JAK2 then orchestrates three distinct, yet highly synchronized, intracellular signaling cascades:

The JAK2–STAT3 Pathway is the canonical and most thoroughly characterized leptin signaling pathway, absolutely required for body weight regulation. Activated JAK2 phosphorylates Tyr1138 on the LepRb tail, creating a high-affinity docking site for the SH2 domain of Signal Transducer and Activator of Transcription 3 (STAT3). Upon docking, STAT3 is phosphorylated by JAK2 at Tyr705, causing it to dissociate from the receptor, homodimerize, and rapidly translocate into the nucleus. Acting as a powerful transcription factor, the STAT3 dimer directly binds to the promoter regions of target genes, robustly upregulating *Pomc* transcription and suppressing *Agrp* transcription (Farooqi et al., 1999). The PI3K–AKT-mTOR Pathway JAK2 activation leads to the phosphorylation of insulin receptor substrate (IRS-1 and IRS-2) proteins. Phosphorylated IRS recruits and activates phosphatidylinositol 3-kinase (PI3K), which generates PIP3, subsequently activating AKT and the mammalian target of rapamycin (mTOR) pathway. This cascade is vital for the rapid electrophysiological changes in the neurons. It modulates the opening of ATP-sensitive potassium (K-ATP) channels and transient receptor potential (TRPC) channels, dictating neuronal firing rates. This pathway represents the major biochemical intersection point between central leptin and insulin signaling. The SHP2–MAPK Pathway**:** The phosphorylation of Tyr985 on LepRb recruits the SH2-containing tyrosine phosphatase 2 (SHP2), which acts as an adaptor protein to activate the extracellular signal-regulated kinase (ERK1/2) cascade (the MAPK pathway). While not strictly required for the acute suppression of food intake, this pathway is heavily implicated in the long-term regulation of energy expenditure and the modulation of efferent sympathetic nerve outflow to cardiovascular tissues and adipose depots (Gautron & Elmquist, 2011; Bruce-Keller et al., 2015). Through the seamless, spatial, and temporal integration of these three molecular pathways, leptin ensures the precise regulation of neuronal firing rates and neuropeptide gene expression, ultimately maintaining long-term global energy homeostasis.

Molecular Mechanisms of Leptin Resistance

Leptin resistance is not defined by a single, isolated molecular defect. Rather, it represents a multifaceted, progressive failure of the leptin signaling axis that occurs at several anatomical and intracellular levels (Cui et al., 2017; Gruzdeva et al., 2019). In the obese state, the continuous barrage of hyperleptinemia and lipotoxicity triggers a cascade of compensatory and pathological mechanisms. These molecular disruptions can be broadly categorized into: impaired blood–brain barrier transport, receptor downregulation, induction of intracellular inhibitors (such as SOCS3), endoplasmic reticulum (ER) stress, and diet-induced neuroinflammation (Engin, 2017; Izquierdo et al., 2019)

Impaired Blood–Brain Barrier (BBB) Transport

For peripherally secreted leptin to activate first-order neurons in the arcuate nucleus, it must successfully traverse the blood–brain barrier (BBB). This transport is highly dependent on a saturable, active transcytosis mechanism mediated primarily by the short isoform of the leptin receptor, LepRa, which is highly expressed in brain capillary endothelial cells (Pan et al., 2014). In lean individuals, the concentration of leptin in the cerebrospinal fluid (CSF) correlates closely with plasma leptin levels. However, in obese subjects, this CSF-to-plasma ratio is drastically reduced (Myers et al., 2010). This "central leptin deficiency" in the face of peripheral hyperleptinemia indicates a primary defect at the level of the BBB (Gruzdeva et al., 2019). The exact mechanisms of this transport impairment involve the saturation of LepRa transporters by chronically high circulating leptin levels. Furthermore, diet-induced hypertriglyceridemia plays a direct pathogenic role; elevated circulating triglycerides have been shown to cross the BBB and directly impair the leptin transport machinery, effectively blinding the hypothalamus to peripheral satiety signals (Myers et al., 2010; Pan et al., 2014).

Receptor Downregulation and Desensitization

A fundamental principle of endocrinology is that chronic exposure to high levels of a hormone leads to the homologous downregulation of its receptor (Engin, 2017). In the context of obesity, persistent hyperleptinemia induces the downregulation of the long signaling isoform, LepRb, on the surface of hypothalamic neurons. This reduction in receptor density severely limits the capacity of the cell to initiate the JAK2–STAT3 signaling cascade (Cui et al., 2017). Additionally, chronic overstimulation leads to receptor desensitization, where the remaining surface receptors become uncoupled from their downstream intracellular effectors, rendering the cell deaf to further leptin stimulation (Izquierdo et al., 2019; Myers et al., 2010).

The Inhibitory Role of SOCS3 and PTP1B

The most critical intracellular blockade of leptin signaling is mediated by negative feedback proteins, primarily the Suppressor of Cytokine Signaling 3 (SOCS3) and Protein Tyrosine Phosphatase 1B (PTP1B) (Cui et al., 2017) (Engin, 2017). SOCS3 under normal conditions, the activation of the JAK2–STAT3 pathway by leptin directly promotes the transcription of the *Socs3* gene. This creates a classic, transient negative feedback loop to prevent cellular overstimulation (Münzberg & Morrison, 2015). However, in obesity, *Socs3* expression in the hypothalamus is chronically upregulated. SOCS3 protein contains a kinase inhibitory region (KIR) and an SH2 domain. It exerts its inhibitory effect by physically binding to phosphorylated Tyr985 on LepRb and directly to JAK2 (Cui et al., 2017; Izquierdo et al., 2019). This steric hindrance prevents STAT3 from docking to the receptor and blocks the catalytic activity of JAK2, effectively shutting down the entire anorexigenic signaling cascade (Engin, 2017). PTP1B is another major intracellular inhibitor is PTP1B, an enzyme localized to the cytoplasmic face of the endoplasmic reticulum. PTP1B directly dephosphorylates the critical tyrosine residues on active JAK2, extinguishing the leptin signal. Studies utilizing neuron-specific PTP1B knockout mice have demonstrated remarkable protection against diet-induced obesity, highlighting its profound role in maintaining leptin resistance (Cui et al., 2017; Izquierdo et al., 2019)

Endoplasmic Reticulum (ER) Stress: A Central Hub for Leptin Resistance

The endoplasmic reticulum (ER) is a highly dynamic, physically continuous membrane network that serves as the primary intracellular organelle responsible for the synthesis, folding, maturation, and trafficking of secretory and transmembrane proteins, as well as for the regulation of intracellular calcium homeostasis and lipid biosynthesis (Cakir & Nillni, 2019). In highly active secretory and metabolically responsive cells, such as the neuropeptide-producing neurons of the arcuate nucleus (ARC), maintaining the functional integrity of the ER is paramount. When the protein-folding capacity of the ER is overwhelmed by excessive metabolic demands, a pathological state known as ER stress ensues (Hosoi & Ozawa, 2016).

The Unfolded Protein Response (UPR) in the Hypothalamus

To mitigate the accumulation of misfolded or unfolded proteins, cells activate a highly conserved, adaptive intracellular signaling network known as the Unfolded Protein Response (UPR). The UPR is governed by three primary transmembrane ER stress sensors: protein kinase RNA-like endoplasmic reticulum kinase (PERK), inositol-requiring enzyme 1 alpha (IRE1α), and activating transcription factor 6 (ATF6) (Cakir & Nillni, 2019; Ramírez & Claret, 2015). Under homeostatic conditions, these sensors are kept in an inactive state through binding with the ER resident chaperone, 78-kDa glucose-regulated protein (GRP78), also known as binding immunoglobulin protein (BiP). During ER stress, BiP dissociates from these sensors to preferentially bind to accumulating misfolded proteins, thereby triggering the UPR Cakir & Nillni, 2019). Initially, the UPR aims to restore homeostasis by halting general protein translation (via PERK-mediated phosphorylation of eIF2α), upregulating ER chaperones (such as BiP and PDIA1), and increasing the clearance of misfolded proteins through ER-associated degradation (ERAD). However, under conditions of chronic overnutrition, the UPR becomes chronically activated and maladaptive, ultimately shifting from a pro-survival mechanism to a pro-apoptotic and pro-inflammatory signaling cascade (Hosoi & Ozawa, 2016; Ramírez & Claret, 2015). Induction of ER Stress by Glucolipotoxicity In the context of obesity, the hypothalamic ER is subjected to immense metabolic stress. High-fat diets (HFD), particularly those rich in saturated fatty acids like palmitate, rapidly induce ER stress in the hypothalamus (Ramírez & Claret, 2015). Unlike unsaturated fatty acids, saturated fats directly disrupt the lipid composition of the ER membrane, altering its fluidity and severely compromising the function of ER membrane proteins, including the Sarco/Endoplasmic Reticulum Ca2+-ATPase pump. The subsequent depletion of luminal ER calcium drastically impairs the function of calcium-dependent chaperones, precipitating widespread protein misfolding (Cakir & Nillni, 2019). The ARC

is acutely vulnerable to this lipotoxicity due to the localized fenestration of the blood-brain barrier (BBB) at the median eminence, which allows circulating free fatty acids to readily access first-order POMC and AgRP neurons (Hosoi & Ozawa, 2016)

Molecular Crosstalk Between UPR and LepRb Signaling

Chronic hypothalamic ER stress profoundly disrupts leptin signaling through multiple converging biochemical pathways. The most critical intersection between ER stress and leptin resistance involves the IRE1α and PERK branches of the UPR (Cakir & Nillni, 2019)Chronic activation of the IRE1α pathway leads to the recruitment of TNF receptor-associated factor 2 (TRAF2), which directly activates c-Jun N-terminal kinase (JNK) and inhibitor of nuclear factor kappa-B kinase subunit beta (IKKβ) (Ramírez & Claret, 2015). The activation of the IKKβ/NF-κB and JNK inflammatory pathways directly induces the transcription of *Socs3* and *Ptp1b*. As previously described, SOCS3 provides potent steric hindrance to JAK2-STAT3 activation, while PTP1B dephosphorylates the activated LepRb complex (Hosoi & Ozawa, 2016). Crucially, PTP1B is itself localized to the cytoplasmic face of the ER membrane, positioning it optimally to respond to ER stress and silence incoming leptin signals (Ramírez & Claret, 2015). Furthermore, active JNK directly phosphorylates insulin receptor substrate 1 (IRS-1) on inhibitory serine residues, simultaneously establishing central insulin resistance.

Impaired Intracellular Trafficking of the Leptin Receptor

Beyond the induction of negative feedback inhibitors, severe ER stress physically prevents the leptin receptor from reaching the cell surface. LepRb is a heavily glycosylated transmembrane protein that requires extensive processing within the ER and Golgi apparatus prior to plasma membrane insertion (Ramírez & Claret, 2015). During severe ER stress, the general suppression of protein translation (via the PERK/eIF2α axis) and the hyperactivation of the ERAD pathway lead to the retention and subsequent degradation of newly synthesized LepRb within the ER (Ramírez & Claret, 2015). Consequently, the density of functional LepRb on the plasma membrane of POMC and AgRP neurons is drastically reduced, rendering the cells physically incapable of detecting circulating leptin, regardless of the hormone's concentration in the cerebrospinal fluid (Hosoi & Ozawa, 2016).

Experimental Evidence and Chemical Chaperones

The causal role of ER stress in leptin resistance is heavily supported by sophisticated transgenic and pharmacological *in vivo* studies. For instance, mice with a neuron-specific deletion of X-box binding protein 1 (XBP1)—a critical transcription factor downstream of the IRE1α pathway required for ER expansion and chaperone production—develop severe leptin resistance, hyperphagia, and diet-induced obesity (Williams et al., 2014). Similarly, the specific deletion of Mitofusin 2 (Mfn2), a protein crucial for mitochondria-ER tethering, exclusively in POMC neurons results in profound ER stress, loss of α-MSH processing, and massive obesity due to a complete loss of leptin responsiveness (Schneeberger et al., 2013). Therapeutically, the administration of chemical chaperones has provided striking validation for this mechanistic link. Pharmacological agents such as 4-phenylbutyrate (4-PBA) and tauroursodeoxycholic acid (TUDCA) function by stabilizing protein conformations and enhancing the folding capacity of the ER (Engin & Hotamisligil, 2010). In experimental rodent models of diet-induced obesity, the central or systemic administration of 4-PBA or TUDCA robustly mitigates hypothalamic ER stress, rapidly restores LepRb-STAT3 signaling, and induces significant weight loss, effectively reversing central leptin resistance (Hosoi & Ozawa, 2016; Engin & Hotamisligil, 2010; Ramírez & Claret, 2015).

Diet-Induced Hypothalamic Inflammation (Neuroinflammation)

Historically, the chronic, low-grade, sterile inflammation associated with obesity—often termed "metaflammation"—was thought to originate exclusively in peripheral white adipose tissue (WAT) due to adipocyte hypertrophy and macrophage infiltration. However, a paradigm-shifting discovery in modern neuroendocrinology revealed that inflammation in the central nervous system, specifically within the hypothalamus, is not merely a secondary consequence of systemic obesity, but rather a primary, initiating event in the pathogenesis of leptin resistance (Dorfman & Thaler, 2015). Strikingly, studies in rodent models have demonstrated that inflammatory markers and gliosis appear in the arcuate nucleus (ARC) within just 24 to 72 hours of high-fat diet (HFD) exposure—long before any significant peripheral weight gain or systemic inflammation is detectable (Saltiel & Olefsky, 2017).

Microglial Activation and TLR4 Signaling

The immunological response within the hypothalamus is heavily orchestrated by microglia, the resident macrophage-like innate immune cells of the central nervous system. In a lean, healthy state, microglia possess a ramified morphology and continuously survey the neural microenvironment to maintain homeostasis. However, the consumption of a high-fat diet, particularly one rich in long-chain saturated fatty acids (such as palmitic and stearic acids), triggers a rapid morphological and functional transformation of these cells into a reactive, amoeboid state—a process known as microgliosis. Saturated fatty acids effectively mimic bacterial lipopolysaccharides (LPS) and are capable of crossing the blood–brain barrier to directly bind and activate Toll-like receptor 4 (TLR4) expressed on the surface of microglia (Mendes et al., 2018; Saltiel & Olefsky, 2017). The engagement of TLR4 recruits the adaptor protein MyD88, which subsequently initiates a robust intracellular signaling cascade culminating in the activation of the IKKβ/NF-κB (Nuclear Factor kappa-light-chain-enhancer of activated B cells) and JNK (c-Jun N-terminal kinase) pathways. The nuclear translocation of NF-κB in microglia drastically upregulates the transcription and secretion of classic pro-inflammatory cytokines, including Tumor Necrosis Factor-alpha (TNF-α), Interleukin-1 beta (IL-1β), and Interleukin-6 (IL-6) (Jais & Brüning, 2017)

Reactive Astrogliosis and Glial-Neuronal Crosstalk

Alongside microgliosis, HFD feeding simultaneously induces the activation of astrocytes, the most abundant glial cell type in the brain, leading to reactive astrogliosis (Dorfman & Thaler, 2015). Astrocytes undergo hypertrophy, upregulate the expression of glial fibrillary acidic protein (GFAP), and participate in a complex, bidirectional inflammatory cross-talk with microglia. Activated astrocytes further amplify the neuroinflammatory milieu by releasing additional cytokines, chemokines (such as CX3CL1), and reactive oxygen species (ROS) into the hypothalamic extracellular space (Douglass et al., 2017). This dense inflammatory network physically surrounds and functionally isolates the leptin-responsive POMC and AgRP neurons. Recent studies have shown that specific inhibition of the IKKβ/NF-κB pathway exclusively in hypothalamic astrocytes is sufficient to protect mice from HFD-induced obesity and leptin resistance, underscoring the indispensable pathogenic role of glial cells (Douglass et al., 2017).

Molecular Mechanism of Cytokine-Induced Leptin Resistance

The pro-inflammatory cytokines (TNF-α, IL-1β, IL-6) secreted by reactive microglia and astrocytes act in a paracrine manner, binding to their respective receptors on the surface of adjacent POMC and AgRP neurons. This paracrine signaling forces the neurons to mount their own intracellular inflammatory response, characterized by the profound activation of neuronal IKKβ/NF-κB and JNK pathways (Dorfman & Thaler, 2015). The activation of these inflammatory kinases directly sabotages the canonical leptin signaling cascade (JAK2-STAT3) through several well-documented mechanisms SOCS3 Upregulation**:** Neuronal NF-κB directly binds to the promoter region of the Socs3 gene, massively upregulating its transcription. The synthesized SOCS3 protein then binds to LepRb and JAK2, providing a physical, steric blockade that prevents STAT3 phosphorylation (Mendes et al., 2018; Saltiel & Olefsky, 2017). Receptor Dephosphorylation inflammatory signaling upregulates PTP1B and other protein tyrosine phosphatases that aggressively dephosphorylate the leptin receptor complex, prematurely terminating the anorexigenic signal (Dorfman & Thaler, 2015). Insulin Resistance Crosstalk activated JNK and IKKβ directly phosphorylate Insulin Receptor Substrate-1 (IRS-1) on inhibitory serine residues (e.g., Ser307). Because the PI3K/AKT pathway downstream of IRS-1 is shared by both leptin and insulin signaling, this inflammatory phosphorylation simultaneously induces central leptin resistance and central insulin resistance, crippling the brain's ability to regulate both appetite and systemic glucose homeostasis (Jais & Brüning, 2017; Saltiel & Olefsky, 2017).

Experimental Depletion of Microglia

The absolute necessity of neuroinflammation in the establishment of leptin resistance has been elegantly proven through microglial depletion models. Pharmacological or genetic ablation of microglia in the hypothalamus of mice fed a high-fat diet results in a remarkable preservation of leptin sensitivity. These microglia-depleted mice exhibit significantly reduced neuronal SOCS3 expression, maintained POMC neuronal firing, and a profound resistance to diet-induced weight gain (Mendes et al., 2018; Valdearcos et al., 2014). Such evidence firmly establishes that diet-induced hypothalamic inflammation is not a bystander effect, but a mandatory molecular bridge linking overnutrition to the neuroendocrine failure of the leptin axis.

Metabolic Consequences of Leptin Resistance

The physiological ramifications of central leptin resistance extend profoundly beyond the mere loss of appetite control and passive weight gain. Because leptin is a pleiotropic hormone deeply integrated into systemic metabolic and autonomic nervous system networks, the disruption of its signaling axis creates a ripple effect that actively drives the pathogenesis of the metabolic syndrome. The failure of the hypothalamic-adipose axis directly precipices severe peripheral metabolic derangements, most notably insulin resistance, lipotoxicity, and cardiovascular dysfunction (Könner & Brüning, 2012; D'Souza et al., 2017).

Central Crosstalk: The Genesis of Insulin Resistance and Type 2 Diabetes

Leptin resistance and insulin resistance are intimately linked, frequently coexisting and mutually exacerbating one another in obese individuals. The foundation of this relationship lies in the remarkable degree of molecular cross-talk between the leptin and insulin signaling cascades within hypothalamic neurons, particularly within the PI3K/AKT and IRS (Insulin Receptor Substrate) pathways. When diet-induced hypothalamic inflammation and chronic hyperleptinemia upregulate the expression of Suppressor of Cytokine Signaling 3 (SOCS3), this inhibitory protein does not exclusively target the LepRb/JAK2 complex. SOCS3 also physically binds to and promotes the ubiquitin-mediated proteasomal degradation of IRS-1 and IRS-2 (Könner & Brüning, 2012; D'Souza et al., 2017). Consequently, central leptin resistance mechanistically forces central insulin resistance. This hypothalamic failure translates into a devastating loss of peripheral glucose homeostasis. In a healthy state, central leptin and insulin signaling act synergistically via the vagus nerve to suppress hepatic gluconeogenesis and glycogenolysis (D'souza et al., 2017). In the resistant state, the brain loses its ability to throttle hepatic glucose production, leading to unremitting fasting hyperglycemia. Furthermore, the continuous hyperphagia resulting from unsuppressed orexigenic drives leads to systemic nutrient overload, heavily taxing pancreatic β-cells, inducing β-cell exhaustion, and inevitably accelerating the clinical progression toward full-blown type 2 diabetes mellitus (T2DM) (Könner & Brüning, 2012; Stern et al., 2016).

Ectopic Lipid Accumulation, Ceramides, and Lipotoxicity

One of the most critical, yet historically underappreciated, functions of leptin is its role as a systemic "liporegulator." Under normal, leptin-sensitive conditions, leptin fiercely protects peripheral, non-adipose tissues from lipid overload. It achieves this by strongly stimulating fatty acid β-oxidation through the activation of AMP-activated protein kinase (AMPK) in skeletal muscle and the liver, while simultaneously downregulating lipogenic enzymes such as Stearoyl-CoA desaturase-1 (SCD-1). In the state of leptin resistance, this protective, anti-steatotic function is completely lost. Consequently, excess dietary triglycerides and free fatty acids (FFAs) that can no longer be safely sequestered in the hypertrophic, dysfunctional white adipose tissue (WAT) overflow into the systemic circulation (Unger & Scherer, 2010). This lipid spillover leads to ectopic fat deposition in peripheral organs. Inside hepatocytes and skeletal myocytes, these lipids are metabolized into highly toxic intermediates, primarily diacylglycerols (DAGs) and ceramides (Unger & Scherer, 2010; Perry et al., 2014). The intracellular accumulation of DAGs and ceramides represents the biochemical hallmark of lipotoxicity. These lipid intermediates directly activate novel Protein Kinase C (nPKC) isoforms (such as PKCθ in muscle and PKCε in the liver) (Perry et al., 2014). Activated PKCs aberrantly phosphorylate IRS-1 on serine/threonine residues, physically blocking its ability to interact with the insulin receptor. In the liver, this lipotoxic mechanism manifests as non-alcoholic fatty liver disease (NAFLD) and severe hepatic insulin resistance. In skeletal muscle, it directly prevents the insulin-stimulated translocation of GLUT4 transporters to the sarcolemma, solidifying profound peripheral insulin resistance (Stern et al., 2016; Perry et al., 2014).

The Paradox of "Selective Leptin Resistance" and Cardiovascular Disease

A particularly fascinating and clinically dangerous phenomenon in obesity neuroendocrinology is the concept of "selective leptin resistance" While the specific pathways governing appetite suppression and metabolic homeostasis (primarily the LepRb → JAK2 → STAT3 axis in the arcuate nucleus) become severely blunted and resistant to leptin, not all hypothalamic responses to leptin are lost. Crucially, the signaling pathways by which leptin drives sympathetic nervous system (SNS) activation—potentially mediated via the PI3K or SHP2/MAPK pathways in the ventromedial (VMH) and dorsomedial hypothalamus (DMH)—often remain entirely preserved, or even become hyper-responsive. Because the obese patient exhibits massive hyperleptinemia, this preserved neural pathway is continuously bombarded by elevated leptin levels.As a result,

chronic hyperleptinemia relentlessly drives efferent sympathetic outflow to the kidneys, heart, and peripheral vasculature. This persistent SNS overdrive significantly increases renal sodium retention, systemic vascular resistance, and resting heart rate. Today, selective leptin resistance is widely recognized as a primary pathogenic driver of obesity-associated arterial hypertension and a major contributor to the elevated cardiovascular morbidity and mortality (such as myocardial infarction and stroke) universally observed in the metabolic syndrome (Simonds et al., 2014; Mark, 2013)

Therapeutic Implications and Future Directions

The profound neuroendocrine realization that human obesity is predominantly driven by a definitive molecular blockade—leptin resistance—rather than a simple behavioral lack of willpower, has fundamentally shifted the landscape of anti-obesity pharmacotherapy (Müller et al., 2018). Historically, the administration of exogenous recombinant human leptin (metreleptin) yielded miraculous results in patients with rare congenital leptin deficiency; however, it completely failed to induce clinically significant weight loss in the general obese population due to preexisting resistance. Consequently, contemporary neuropharmacological research is intensely focused on strategies that either actively resensitize the hypothalamic axis to endogenous leptin or utilize polypharmacology to bypass the saturated signaling roadblocks (Müller et al., 2018; Liu et al., 2015)

Discovery of Novel Leptin Sensitizers

A major breakthrough in obesity therapeutics has been the identification of small-molecule compounds capable of acting as "leptin sensitizers." These molecules do not activate the leptin receptor directly; rather, they clear the intracellular bottlenecks preventing JAK2-STAT3 signal transduction (Zabeau et al., 2021). The most prominent example is Celastrol, a pentacyclic triterpene extracted from the roots of the *Tripterygium wilfordii* plant. In landmark preclinical studies, Celastrol was shown to drastically reduce food intake and induce up to a 45% loss of body weight in hyperleptinemic, diet-induced obese (DIO) mice (Liu et al., 2015). Celastrol functions by robustly suppressing hypothalamic endoplasmic reticulum (ER) stress and enhancing the folding capacity of the ER, thereby allowing LepRb to properly traffic to the neuronal surface (Liu et al., 2015; Zabeau et al., 2021). Another highly promising compound is Withaferin A, a steroidal lactone derived from *Withania somnifera*. Similar to Celastrol, Withaferin A reverses central leptin resistance, but it simultaneously acts as a potent insulin sensitizer in peripheral tissues, significantly ameliorating hepatic steatosis and reducing circulating ceramide levels (Lee et al., 2016). The ongoing chemical optimization of these natural sensitizers to improve their safety profiles and bioavailability represents a massive frontier for future clinical trials (Zabeau et al., 2021).

Incretin Mimetics and Polypharmacology

Currently, the most effective pharmacological treatments for obesity are glucagon-like peptide-1 (GLP-1) receptor agonists (e.g., liraglutide, semaglutide) and dual GLP-1/GIP receptor agonists (e.g., tirzepatide). While these incretin mimetics act primarily through their own distinct neuroendocrine receptors in the arcuate nucleus, hindbrain, and vagus nerve to suppress appetite, their success is deeply intertwined with the leptin axis. Research indicates that GLP-1 receptor agonists are highly effective because they completely bypass the impaired leptin signaling pathways. By directly activating POMC/CART neurons via independent intracellular mechanisms (such as cAMP/PKA), GLP-1 analogs successfully suppress feeding behavior even in states of severe leptin resistance (Secher et al., 2014) Crucially, as incretin therapy induces initial weight loss, the reduction in systemic fat mass decreases the lipotoxic burden and alleviates hypothalamic neuroinflammation. This secondary reduction in ER stress and SOCS3 expression gradually *restores* endogenous leptin sensitivity (Clemmensen et al., 2014, Müller et al., 2015). Furthermore, groundbreaking preclinical trials have demonstrated that combinatorial therapies—such as co-administering a GLP-1/glucagon co-agonist alongside exogenous leptin—produce massive, synergistic weight loss (Clemmensen et al., 2014 (Müller et al., 2015). Once the incretin component partially clears the hypothalamic inflammation, the brain becomes resensitized, allowing the co-administered leptin to successfully exert its powerful anorexigenic and thermogenic effects (Clemmensen et al., 2014). This multi-hormonal "polyagonist" approach is currently considered the most promising future strategy to permanently overcome the deeply entrenched metabolic defense mechanisms of severe obesity.

Conclusions

Leptin resistance is a central, driving pathological mechanism in the development and maintenance of obesity and its associated metabolic disorders. It is a complex, multifactorial phenomenon characterized by the failure of circulating leptin to effectively penetrate the blood–brain barrier and activate its canonical intracellular signaling pathways. This neuroendocrine failure is primarily orchestrated by the maladaptive upregulation of intracellular inhibitors such as SOCS3 and PTP1B, the onset of severe endoplasmic reticulum (ER) stress, and diet-induced hypothalamic neuroinflammation mediated by microglial and astrocytic activation. The resultant disruption of energy homeostasis leads to a vicious cycle of chronic hyperphagia, reduced energy expenditure, and systemic lipotoxicity, directly bridging obesity with insulin resistance, non-alcoholic fatty liver disease (NAFLD), and cardiovascular dysfunction. A deep, molecular understanding of the leptin resistance paradigm is absolutely essential for the advancement of modern endocrinology. Only by identifying and clinically targeting these specific neuroendocrine roadblocks—whether through novel leptin sensitizers like Celastrol, or through advanced incretin-based polypharmacology—can the medical community develop highly effective, targeted therapies capable of restoring metabolic health in the global fight against the obesity pandemic.

Author's contribution:

Conceptualisation and project administration: Karol Dąbek

Methodology: Urszula Marzec and Kamila Czyżak

Validation: Aleksandra Cyrkler and Natalia Cieślak

Formal analysis and investigation: Karol Dąbek and Eliza Rajca

Resources: Agnieszka Giza and Paulina Giza

Data curation: Karol Dąbek, Karolina Wymoczył, Agata Chodkowska

Writing – original draft, review & editing: Karol Dąbek, Kamila Czyżak, Urszula Marzec, Aleksandra Cyrkler, Natalia Cieślak, Agata Chodkowska, Eliza Rajca, Agnieszka Giza, Paulina Giza, Karolina Wymoczył.

Visualisation and supervision: Karol Dąbek

All authors have read and agreed with the published version of the manuscript.

Funding Statement: The study did not receive special funding.

Conflict of Interest Statement: The authors declare no conflict of interest.

Declaration of the use of generative AI and AI-assisted technologies in the writing process: In preparing this work, the authors used Google Gemini for the purpose of improving language, grammar correction, text formatting. After using this tool, the authors reviewed and edited the text as needed and accept full responsibility for the substantive content of the publication.

REFERENCES

1. Cui, H., López, M., & Rahmouni, K. (2017). The cellular and molecular bases of leptin and ghrelin resistance in obesity. *Nature Reviews Endocrinology, 13*(6), 338–351. https://doi.org/10.1038/nrendo.2016.222
2. de Git, K. C., & Adan, R. A. (2015). Leptin resistance in diet-induced obesity: The role of hypothalamic inflammation. *Obesity Reviews, 16*(3), 207–224. https://doi.org/10.1111/obr.12243
3. Engin, A. (2017). Human protein kinases and obesity. *Advances in Experimental Medicine and Biology, 960*, 111–134. https://doi.org/10.1007/978-3-319-48382-5_5
4. Gruzdeva, O., Borodkina, D., Uchasova, E., Dyleva, Y., & Barbarash, O. (2019). Leptin resistance: Underlying mechanisms and diagnosis. *Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 12*, 191–198. https://doi.org/10.2147/DMSO.S182406
5. Hosoi, T., & Ozawa, K. (2016). Possible pharmacological approach targeting endoplasmic reticulum stress to ameliorate leptin resistance in obesity. *Frontiers in Endocrinology, 7*, Article 59. https://doi.org/10.3389/fendo.2016.00059
6. Izquierdo, A. G., Crujeiras, A. B., Casanueva, F. F., & Carreira, M. C. (2019). Leptin, obesity, and leptin resistance: Where are we 25 years later? *Nutrients, 11*(11), Article 2704. https://doi.org/10.3390/nu11112704
7. Münzberg, H., & Morrison, C. D. (2015). Structure, production and signaling of leptin. *Metabolism: Clinical and Experimental, 64*(1), 13–23. https://doi.org/10.1016/j.metabol.2014.09.010
8. Myers, M. G., Jr., Leibel, R. L., Seeley, R. J., & Schwartz, M. W. (2010). Obesity and leptin resistance: Distinguishing cause from effect. *Trends in Endocrinology and Metabolism, 21*(11), 643–651. https://doi.org/10.1016/j.tem.2010.08.002

9. Obradovic, M., Sudar-Milovanovic, E., Soskic, S., Essack, M., Arya, S., Stewart, A. J., Gojobori, T., & Isenovic, E. R. (2021). Leptin and obesity: Role and clinical implication. *Frontiers in Endocrinology, 12*, Article 585887. https://doi.org/10.3389/fendo.2021.585887
10. Pan, H., Guo, J., & Su, Z. (2014). Advances in understanding the interrelations between leptin resistance and obesity. *Physiology & Behavior, 130*, 157–169. https://doi.org/10.1016/j.physbeh.2014.04.003
11. Cakir, I., & Nillni, E. A. (2019). Endoplasmic reticulum stress, the hypothalamus, and energy balance. *Trends in Endocrinology and Metabolism, 30*(3), 163–176. https://doi.org/10.1016/j.tem.2019.01.002
12. Engin, F., & Hotamisligil, G. S. (2010). Restoring endoplasmic reticulum function by chemical chaperones: An emerging therapeutic approach for metabolic diseases. *Diabetes, Obesity and Metabolism, 12*(Suppl. 2), 108–115. https://doi.org/10.1111/j.1463-1326.2010.01282.x
13. Hosoi, T., & Ozawa, K. (2016). Possible pharmacological approach targeting endoplasmic reticulum stress to ameliorate leptin resistance in obesity. *Frontiers in Endocrinology, 7*, Article 59. https://doi.org/10.3389/fendo.2016.00059
14. Ramírez, S., & Claret, M. (2015). Hypothalamic ER stress: A bridge between leptin resistance and obesity. *FEBS Letters, 589*(14), 1678–1687. https://doi.org/10.1016/j.febslet.2015.04.025
15. Schneeberger, M., Dietrich, M. O., Sebastián, D., Imbernón, M., Castaño, C., Garcia, A., Esteban, Y., Gonzalez-Franquesa, A., Rodríguez, I. C., Bortolozzi, A., Garcia-Roves, P. M., Gomis, R., Nogueiras, R., Horvath, T. L., Zorzano, A., & Claret, M. (2013). Mitofusin 2 in POMC neurons connects ER stress with leptin resistance and energy imbalance. *Cell, 155*(1), 172–187. https://doi.org/10.1016/j.cell.2013.09.003
16. Williams, K. W., Liu, T., Kong, X., Fukuda, M., Deng, Y., Berglund, E. D., Deng, Z., Gao, Y., Liu, T., Sohn, J. W., Jia, L., Fujikawa, T., Kohno, D., Scott, M. M., Lee, S., Lee, C. E., Sun, K., Chang, Y., Scherer, P. E., & Elmquist, J. K. (2014). Xbp1s in POMC neurons connects ER stress with energy balance and glucose homeostasis. *Cell Metabolism, 20*(3), 471–482. https://doi.org/10.1016/j.cmet.2014.06.002
17. Jais, A., & Brüning, J. C. (2017). Hypothalamic inflammation in obesity and metabolic disease. *The Journal of Clinical Investigation, 127*(1), 24–32. https://doi.org/10.1172/JCI88878
18. Valdearcos, M., Robblee, M. M., Benjamin, D. I., Nomura, D. K., Xu, A. W., & Koliwad, S. K. (2014). Microglia dictate the impact of saturated fat consumption on hypothalamic inflammation and neuronal function. *Cell Reports, 9*(6), 2124–2138. https://doi.org/10.1016/j.celrep.2014.11.018
19. Dorfman, M. D., & Thaler, J. P. (2015). Hypothalamic inflammation and gliosis in obesity. *Current Opinion in Endocrinology, Diabetes, and Obesity, 22*(5), 325–330. https://doi.org/10.1097/MED.0000000000000182
20. Baufeld, C., Osterloh, A., Prokop, S., Miller, K. R., & Heppner, F. L. (2016). High-fat diet-induced brain region-specific phenotypic spectrum of CNS resident microglia. *Acta Neuropathologica, 132*(3), 361–375. https://doi.org/10.1007/s00401-016-1595-4
21. Mendes, N. F., Kim, Y. B., Velloso, L. A., & Araújo, E. P. (2018). Hypothalamic microglial activation in obesity: A mini-review. *Frontiers in Neuroscience, 12*, Article 846. https://doi.org/10.3389/fnins.2018.00846
22. Douglass, J. D., Dorfman, M. D., Fasnacht, R., Shaffer, L. D., & Thaler, J. P. (2017). Astrocyte IKKβ/NF-κB signaling is required for diet-induced obesity and hypothalamic inflammation. *Molecular Metabolism, 6*(4), 366–373. https://doi.org/10.1016/j.molmet.2017.01.010
23. Saltiel, A. R., & Olefsky, J. M. (2017). Inflammatory mechanisms linking obesity and metabolic disease. *The Journal of Clinical Investigation, 127*(1), 1–4. https://doi.org/10.1172/JCI92035
24. Simonds, S. E., Pryor, J. T., Ravussin, E., Greenway, F. L., Dileone, R., Allen, A. M., Bassi, J., Elmquist, J. K., Keogh, J. M., Henning, E., Myers, M. G., Jr., Licinio, J., Brown, R. D., Enriori, P. J., O'Rahilly, S., Sternson, S. M., Grove, K. L., Spanswick, D. C., Farooqi, I. S., & Cowley, M. A. (2014). Leptin mediates the increase in blood pressure associated with obesity. *Cell, 159*(6), 1404–1416. https://doi.org/10.1016/j.cell.2014.10.058
25. Könner, A. C., & Brüning, J. C. (2012). Selective insulin and leptin resistance in metabolic disorders. *Cell Metabolism, 16*(2), 144–152. https://doi.org/10.1016/j.cmet.2012.07.004
26. Unger, R. H., & Scherer, P. E. (2010). Gluttony, sloth and the metabolic syndrome: A roadmap to lipotoxicity. *Trends in Endocrinology and Metabolism, 21*(6), 345–352. https://doi.org/10.1016/j.tem.2010.01.009
27. Stern, J. H., Rutkowski, J. M., & Scherer, P. E. (2016). Adiponectin, leptin, and fatty acids in the maintenance of metabolic homeostasis through adipose tissue crosstalk. *Cell Metabolism, 23*(5), 770–784. https://doi.org/10.1016/j.cmet.2016.04.011
28. Mark, A. L. (2013). Selective leptin resistance revisited. *American Journal of Physiology-Regulatory, Integrative and Comparative Physiology, 305*(6), R566–R581. https://doi.org/10.1152/ajpregu.00180.2013
29. D'souza, A. M., Neumann, U. H., Glavas, M. M., & Kieffer, T. J. (2017). The glucoregulatory actions of leptin. *Molecular Metabolism, 6*(9), 1052–1065. https://doi.org/10.1016/j.molmet.2017.04.011
30. Perry, R. J., Samuel, V. T., Petersen, K. F., & Shulman, G. I. (2014). The role of hepatic lipids in hepatic insulin resistance and type 2 diabetes. *Nature, 510*(7503), 84–91. https://doi.org/10.1038/nature13478
31. Liu, J., Lee, J., Salazar Hernandez, M. A., Mazitschek, R., & Ozcan, U. (2015). Treatment of obesity with celastrol. *Cell, 161*(5), 999–1011. https://doi.org/10.1016/j.cell.2015.05.011
32. Lee, J., Liu, J., Feng, X., Salazar Hernández, M. A., Mucka, P., Ibi, D., Choi, J. W., & Ozcan, U. (2016). Withaferin A is a leptin sensitizer with strong antidiabetic properties in mice. *Nature Medicine, 22*(9), 1023–1032. https://doi.org/10.1038/nm.4145
33. Clemmensen, C., Chabenne, J., Finan, B., Sullivan, L., Fischer, K., Küchler, D., Sehrer, L., Ograjsek, T., Hofmann, S. M., Schriever, S. C., Pfluger, P. T., Pinkstaff, J., Tschöp, M. H., Dimarchi, R., & Müller, T. D. (2014). GLP-1/glucagon coagonism restores leptin responsiveness in obese mice chronically maintained on an obesogenic diet. *Diabetes, 63*(4), 1422–1427. https://doi.org/10.2337/db13-1609

34. Secher, A., Jelsing, J., Baquero, A. F., Hecksher-Sørensen, J., Cowley, M. A., Dalbøge, L. S., Hansen, G., Grove, K. L., Pyke, C., Raun, K., Schäffer, L., Tang-Christensen, M., Verma, S., Witgen, B. M., Vrang, N., & Bjerre Knudsen, L. (2014). The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss. *The Journal of Clinical Investigation, 124*(10), 4473–4488. https://doi.org/10.1172/JCI75276
35. Zhao, S., Kusminski, C. M., & Scherer, P. E. (2021). Adiponectin, leptin and cardiovascular disorders. *Circulation Research, 128*(1), 136–149. https://doi.org/10.1161/CIRCRESAHA.120.314458
36. Müller, T. D., Clemmensen, C., Finan, B., DiMarchi, R. D., & Tschöp, M. H. (2018). Anti-obesity therapy: From rainbow pills to polyagonists. *Pharmacological Reviews, 70*(4), 712–746. https://doi.org/10.1124/pr.117.014803
37. Liu, J., Lee, J., Salazar Hernandez, M. A., Mazitschek, R., & Ozcan, U. (2015). Treatment of obesity with celastrol. *Cell, 161*(5), 999–1011. https://doi.org/10.1016/j.cell.2015.05.011
38. World Health Organization. (2021). Obesity and overweight. https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight
39. Neel, J. V. (1962). Diabetes mellitus: A “thrifty” genotype rendered detrimental by “progress”? *American Journal of Human Genetics, 14*(4), 353–362.
40. Coleman, D. L. (1978). Obese and diabetes: Two mutant genes causing diabetes-obesity syndromes in mice. *Diabetologia, 14*(3), 141–148. https://doi.org/10.1007/BF00429772
41. Montague, C. T., Farooqi, I. S., Whitehead, J. P., Soos, M. A., Rau, H., Wareham, N. J., Sewter, C. P., Digby, J. E., Mohammed, S. N., Hurst, J. A., Cheetham, C. H., Earley, A. R., Barnett, A. H., Prins, J. B., & O'Rahilly, S. (1997). Congenital leptin deficiency is associated with severe early-onset obesity in humans. *Nature, 387*(6636), 903–908. https://doi.org/10.1038/43185
42. Farooqi, I. S., Jebb, S. A., Langmack, G., Lawrence, E., Cheetham, C. H., Prentice, A. M., Hughes, I. A., McCamish, M. A., & O'Rahilly, S. (1999). Effects of recombinant leptin therapy in a child with congenital leptin deficiency. *The New England Journal of Medicine, 341*(12), 879–884. https://doi.org/10.1056/NEJM199909163411204
43. Tartaglia, L. A., Dembski, M., Weng, X., Deng, N., Culpepper, J., Devos, R., Richards, G. J., Campfield, L. A., Clark, F. T., Deeds, J., Muir, C., Sanker, S., Moriarty, A., Moore, K. J., Smutko, J. S., Mays, G. G., Wool, E. A., Monroe, C. A., & Tepper, R. I. (1995). Identification and expression cloning of a leptin receptor, OB-R. *Cell, 83*(7), 1263–1271. https://doi.org/10.1016/0092-8674(95)90151-5
44. Gautron, L., & Elmquist, J. K. (2011). Sixteen years and counting: An update on leptin in energy balance. *The Journal of Clinical Investigation, 121*(6), 2087–2093. https://doi.org/10.1172/JCI45888
45. Balland, E., Dam, J., Langlet, F., Caron, E., Steculorum, S., Messina, A., Rasika, S., Falluel-Morel, A., Anouar, Y., Dehouck, B., Trinquet, E., Jockers, R., Bouret, S. G., & Prévot, V. (2014). Hypothalamic tanycytes are an ERK-gated conduit for leptin into the brain. *Cell Metabolism, 19*(2), 293–301. https://doi.org/10.1016/j.cmet.2013.12.015
46. Park, H. K., & Ahima, R. S. (2015). Physiology of leptin: Energy homeostasis, neuroendocrine function and metabolism. *Metabolism: Clinical and Experimental, 64*(1), 24–34. https://doi.org/10.1016/j.metabol.2014.08.004
47. Vaisse, C., Halaas, J. L., Horvath, C. M., Darnell, J. E., Jr., Stoffel, M., & Friedman, J. M. (1996). Leptin activation of Stat3 in the hypothalamus of wild-type and ob/ob mice but not db/db mice. *Nature Genetics, 14*(1), 95–97. https://doi.org/10.1038/ng0996-95
48. Kelesidis, T., Kelesidis, I., Chou, S., & Mantzoros, C. S. (2010). Narrative review: The role of leptin in human physiology: Emerging clinical applications. *Annals of Internal Medicine, 152*(2), 93–100. https://doi.org/10.7326/0003-4819-152-2-201001190-00008
49. Flier, J. S. (2004). Obesity wars: Molecular progress confronts an expanding epidemic. *Cell, 116*(2), 337–350. https://doi.org/10.1016/S0092-8674(03)01081-X
50. Cani, P. D., Amar, J., Iglesias, M. A., Poggi, M., Knauf, C., Bastelica, D., Neyrinck, A. M., Fava, F., Tuohy, K. M., Chabo, C., Waget, A., Delmée, E., Cousin, B., Sulpice, T., Chamontin, B., Ferrières, J., Tanti, J. F., Gibson, G. R., Casteilla, L., Delzenne, N. M., ... Burcelin, R. (2007). Metabolic endotoxemia initiates obesity and insulin resistance. *Diabetes, 56*(7), 1761–1772. https://doi.org/10.2337/db06-1491
51. Clegg, D. J., Brown, L. M., Woods, S. C., & Benoit, S. C. (2006). Gonadal hormones determine sensitivity to central leptin and insulin. *Diabetes, 55*(4), 978–987. https://doi.org/10.2337/diabetes.55.04.06.db05-1339
52. Wang, J., Zhang, X., Zhu, Y., Sun, H., Chen, X., Zhao, Z., Zhang, N., Zhang, C., Li, L., & Bi, Y. (2026). Adipocyte-derived extracellular vesicles are key regulators of central leptin sensitivity and energy homeostasis. *Cell Metabolism, 38*(1), 82–99.e8. https://doi.org/10.1016/j.cmet.2025.10.005
53. Plagemann, A. (2006). Maternal diabetes and perinatal programming. *Early Human Development, 82*(8), 523–528. https://doi.org/10.1016/j.earlhumdev.2006.05.008
54. Varela, L., & Horvath, T. L. (2012). Leptin and agouti-related protein in energy balance. *Endocrinology, 153*(12), 5644–5651. https://doi.org/10.1210/en.2012-1678
55. Bruce-Keller, A. J., Salbaum, J. M., Luo, M., Blanchard, E., IV, Taylor, C. M., Welsh, D. A., & Berthoud, H. R. (2015). Obese-type gut microbiota induce neurobehavioral changes in the absence of obesity. *Biological Psychiatry, 77*(7), 607–615. https://doi.org/10.1016/j.biopsych.2014.07.012